• Higher-risk: hypomethylating agents (±venetoclax) • Lower-risk: agent to reduce transfusion needs (ESA, lenalidomide) • Del (5q) syndrome: lenalidomide • Lowering transfusion episodes if possible, by lowering the threshold for Hb (<7 g/dl) and platelets (<10 × 109/L) • G-CSF to shorter neutropenia • Transfusion as for AML. The gene discussed is CSF3; the disease is neutropenia.